Another week, another study finding that Ozempic/Wegovy and similar drugs may do a lot more than just help people lose weight. New research has found that patients who start taking GLP-1 drugs are less likely to be diagnosed with depression and anxiety afterward, compared to similar patients not on the drug. The findings do not … Read more
Your snack habit may be even more calorie-dense than you think, recent research suggests. A study estimated that snacking contributes to around 20% of an average American’s daily caloric intake, and these snacks often add little nutritional value. The scientists found, though, that people with type 2 diabetes seem to eat fewer snack-related calories. Google’s … Read more
CFOTO | Future Publishing | Getty Images Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly … Read more
Add it to the laundry list of reasons to prioritize sleep: Getting adequate rest each night may reduce your risk of developing type 2 diabetes, according to the results of a study published this week in Diabetes Care. Earlier research points to sleep loss as a risk factor for many chronic diseases, including diabetes and … Read more
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound. The New M3-Powered iMacs Are … Read more
The ever-evolving Apple Watch is rumored to be getting even more health monitoring features in 2024, with reports that the devices will expand to three additional sensors that can warn users if they are prediabetic, sense rising blood pressure, and alert someone if they may have sleep apnea. The portable devices, Apple’s tentpole health and … Read more
Two experts see major challenges facing the adoption of new obesity drugs. Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic’s ability to delay the progression of chronic kidney disease is among the strongest supporting evidence for secondary uses of the drug. However, she considers data … Read more